Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Vanda Pharmaceuticals Inc. (VNDA) is a Biotechnology company based in US with a market capitalization of $329.5M. Revenue grew 8.7% year-over-year and free cash flow was negative at -$110.4M. This page tracks VNDA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 368 employees · IPO Apr 12, 2006

Valuation

Valuation & price

$6.28as of May 17, 2026· -34.3% vs 52w high

P/E ratio

Latest-FY diluted EPS

1.01

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$9.56$6.88$4.19Jul 25Jan 26Jul 26
$4.1952-week range$9.56
Loading valuation history…

Fundamentals

Key fundamentals

$329.5M

Market cap

8.7%

Revenue growth (YoY)

94.0%

Gross margin

-$110.4M

Free cash flow (USD)

-$251.2M

Net debt

Net cash position

1.3%

Share dilution

2/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$146M$216.1M

Free cash flow by year

20162025

-$9.5M-$110.4M

Gross margin by year

20212025

90.5%94.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventJun 5, 2026Filing

    Annual Meeting Results

  • Quarterly reportMay 7, 2026Filing

    10-Q Filed

  • 8-K eventMay 6, 2026Filing

    Earnings Release

  • 8-K eventApr 22, 2026Filing

    Director Appointment

  • 8-K eventApr 2, 2026Filing

    Executive Resignation

Questions

Frequently asked questions

What is Vanda Pharmaceuticals Inc.'s market cap?

Vanda Pharmaceuticals Inc. (VNDA) has a market capitalization of $329.5M.

What is VNDA's P/E ratio?

A meaningful P/E ratio is not available for VNDA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is VNDA's price-to-book (P/B) ratio?

VNDA trades at 1.01 times book value per share.

Are insiders buying VNDA stock?

SEC Form 4 filings show no open-market insider buys at Vanda Pharmaceuticals Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.